trial · primary record
Osimertinib
Non-Small Cell Lung Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 41 |
| Primary completion | 2029-12-31 |
| Primary endpoint | Intracranial objective response rate (iORR) |
| Registry ID | NCT07911449 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:45.084Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07911449
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Osimertinib · compound